TY - JOUR
T1 - Acute effects of triazolam and lorazepam on human learning, performance and subject ratings
AU - Rush, C. R.
AU - Higgins, S. T.
AU - Bickel, W. K.
AU - Hughes, J. R.
PY - 1993
Y1 - 1993
N2 - Triazolam (0, 0.125, 0.25, 0.5 and 0.75 mg/70 kg) and lorazepam (0, 1, 2, 4 and 6 mg/70 kg) were compared in eight healthy men by using a double- blind, crossover design. Triazolam was chosen for study to examine experimentally whether it produces greater behavioral impairment than other benzodiazepines as reported previously. Lorazepam was chosen as the comparison drug because of its well documented behavioral effects and because it has a short metabolic half-life and no active metabolite, which eliminates the possible confounding effects of drug accumulation. Drug effects were assessed before and every 30 min for 8 hr after drug administration. Learning was chosen for study because it is a fundamental component of more complex behavioral processes such as recall, and benzodiazepines are known to disrupt learning. A psychomotor task and subject-rating scales, assessing drug effects and abuse potential, were also included to provide a more comprehensive comparison of these compounds. Triazolam and lorazepam dose- dependently disrupted learning and psychomotor performance and increased subject ratings of sedation to a comparable degree. These findings do not support allegations that triazolam produces greater behavioral impairment than other commonly used benzodiazepines.
AB - Triazolam (0, 0.125, 0.25, 0.5 and 0.75 mg/70 kg) and lorazepam (0, 1, 2, 4 and 6 mg/70 kg) were compared in eight healthy men by using a double- blind, crossover design. Triazolam was chosen for study to examine experimentally whether it produces greater behavioral impairment than other benzodiazepines as reported previously. Lorazepam was chosen as the comparison drug because of its well documented behavioral effects and because it has a short metabolic half-life and no active metabolite, which eliminates the possible confounding effects of drug accumulation. Drug effects were assessed before and every 30 min for 8 hr after drug administration. Learning was chosen for study because it is a fundamental component of more complex behavioral processes such as recall, and benzodiazepines are known to disrupt learning. A psychomotor task and subject-rating scales, assessing drug effects and abuse potential, were also included to provide a more comprehensive comparison of these compounds. Triazolam and lorazepam dose- dependently disrupted learning and psychomotor performance and increased subject ratings of sedation to a comparable degree. These findings do not support allegations that triazolam produces greater behavioral impairment than other commonly used benzodiazepines.
UR - http://www.scopus.com/inward/record.url?scp=0027438376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027438376&partnerID=8YFLogxK
M3 - Article
C2 - 8450459
AN - SCOPUS:0027438376
SN - 0022-3565
VL - 264
SP - 1218
EP - 1226
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 3
ER -